Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Wagstaff & Cartmell Announces Alabama Federal Court Denies Motion to Dismiss PROZAC® Suit
  • USA - English


News provided by

Wagstaff Cartmell

Jul 24, 2015, 15:20 ET

Share this article

Share toX

Share this article

Share toX


Montgomery, AL (PRWEB) July 24, 2015 -- U.S. District Chief Judge Keith Watkins for the Middle District of Alabama recently denied defendant Eli Lilly and Company's (Lilly) motion to dismiss a suit against it by plaintiff Dana Fields, who claims taking the pharmaceutical company’s antidepressant PROZAC for eight months during her pregnancy caused her son to be born with a congenital heart defect.

While Dana’s son continues to undergo treatment for his complex heart defect, we are glad she enjoyed this small victory. We are looking forward to the further pursuit of these claims.

Post this

Judge Watkins dismissed the motion based on a dispute over Fields' use of the antidepressant. Specifically, the court ruled Fields could still show “factual causation” that her late doctor would have prescribed a different medication if Lilly issued stronger warnings back in 1996.

Joseph Zonies and Mark Premo-Hopkins, partners at Reilly Pozner in Denver, Co. and Thomas P. Cartmell and Christopher L. Schnieders, partners at Wagstaff & Cartmell in Kansas City, Mo. represent the plaintiff, along with and Richard A. Freese, principal at Freese & Goss in Dallas, Texas.

“All of us are pleased that the court denied the motion to dismiss this case,” said Schnieders. “While Dana’s son continues to undergo treatment for his complex heart defect, we are glad she enjoyed this small victory. We are looking forward to the further pursuit of these claims.”

According to court documents, Fields is seeking monetary recovery from Lilly, the drug’s manufacturer, claiming that her son was born on Jan. 29, 1997 with a congenital heart defect called Tetralogy of Fallot (along with moderate pulmonary valve insufficiency) caused by her ingestion of the prescription drug PROZAC during the first eight months of her pregnancy. Tetralogy of Fallot is a rare condition caused by a combination of four heart defects that affect the structure of the heart and cause oxygen-deficient blood to flow into the body.

Fields’ action, filed in January 2013, focuses on Lilly’s alleged failure in 1996 to provide adequate warnings about the risks of PROZAC causing birth defects if used during pregnancy. The U.S. Food and Drug Administration approved Lilly’s marketing of the drug in 1987, according to court documents.

In the motion, Lilly argued that Fields could not support her claims with enough evidence that she actually took PROZAC during her pregnancy. Lilly also said in the motion that the only support of her claims is "self-serving" testimony from Fields, as well as her husband, that she took the medication. Lilly went on to point out in the motion that there was no evidence in her medical records or a “leftover pill bottle,” according to court documents.

However, in the order, Judge Watkins sided with Fields’ argument, saying “the testimony’s self-serving nature will not bar its consideration at the summary-judgment stage so long as the deponent (Mrs. Fields) and the declarant (Mr. Fields) are competent, the testimony is based on personal knowledge and the testimony contains facts that would be admissible at trial. These three prerequisites are met.”

Lilly also argued in the motion that Fields could not sufficiently support her claims against the company’s “failure to warn” because her doctor who prescribed the PROZAC died in 2009, four years before she filed her lawsuit. Therefore Lilly contested in the motion that without testimony from her doctor, she cannot show that he would have prescribed something different based on warnings from the drug manufacturer about possible birth defects.

Additionally, Fields presented “subjective evidence” about her doctor’s practices based on his nurse’s testimony in a deposition. Due to this testimony, and that the nurse had worked with the doctor for 12 years, Judge Watkins wrote in the order that Fields should continue pursuing her claims under this “subjective evidence standard.”

Wagstaff & Cartmell lawyers are often named to the plaintiffs’ leadership teams of the country’s largest drug and device cases in multi-district litigation (MDL).

In the United States District Court for the Middle District of Alabama Northern Division

Case No. 2:13-CV-35-WKW [WO] - Memorandum Opinion and Order

Dana Fields, Individually and as Natural Parent of D.F., a Minor, Plaintiff
v. Eli Lilly and Company, Defendant

Contacts:

Joseph Zonies
Reilly Pozner
303-893-6110
jzonies(at)rplaw(dot)com

Tom Cartmell
Wagstaff & Cartmell
816-701-1102
tcartmell(at)wcllp(dot)com

Christopher L. Schnieders
Wagstaff & Cartmell
816-701-1145
cschnieders(at)wcllp(dot)com

Mark Premo-Hopkins
Reilly Pozner
303-893-6110
jzonies(at)rplaw(dot)com

Richard A. Freese
Freese & Goss
205-871-4144
rich(at)freeseandgoss(dot)com

MEDIA CONTACT:

Justin Scott
Scott Communications
816-809-3116
justin(at)scott-comms(dot)com

Tom Cartmell, Wagstaff Cartmell, http://www.wagstaffcartmell.com, +1 816-809-3116, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.